Next Science (ASX:NXS) - Managing Director, Judith Mitchell
Managing Director, Judith Mitchell
Source: Women in STEMM Australia
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Next Science (NXS) has seen its XPERIENCE Surgical Solution cleared by Australia’s Therapeutic Goods Administration (TGA)
  • The TGA clearance allows for the sale of the no-rinse, antimicrobial solution in Australia
  • The company says it has received attention from organisations interested in partnering with Next Science, and is now in the process of evaluating commercialisation options for bringing XPERIENCE to the Australian market
  • Next Science shares were up 2.03 per cent, trading at $1.26 at 4:00 pm AEDT 

Next Science (NXS) has seen its XPERIENCE Surgical Solution cleared by Australia’s Therapeutic Goods Administration (TGA).

XPERIENCE is designed for use in open surgical procedures where the residual solution remains in the surgical site after closure. The no-rinse, antimicrobial solution is designed to defend against pathogens for several hours by rinsing away debris and micro-organisms, giving surgeons a simple adjunct to help prevent surgical site and post-operative infections.

The TGA clearance allows for the sale of XPERIENCE in Australia.

XPERIENCE is currently sold in the US market where the product received a 510(k) clearance from the US Food and Drug Administration (FDA) in April this year.

The initial sales focus for XPERIENCE in the US has been the orthopaedic, plastic and reconstructive surgery markets.

“Surgical site infections are a major cause of surgical complications and increased morbidity and mortality across the world,” explained Managing Director Judith Mitchell.

“XPERIENCE provides an enormous opportunity to help reduce surgical site infections, save lives and reduce healthcare costs that arise from perioperative infections.”

The company said it has received strong inbound attention from organisations interested in partnering with Next Science, and is now in the process of evaluating commercialisation options for bringing XPERIENCE to the Australian market.

Next Science shares were up 2.03 per cent, trading at $1.26 at 4:00 pm AEDT.

NXS by the numbers
More From The Market Herald
Countplus (ASX:CUP) - Incoming CEO, Hugh Humphrey

" Hugh Humphrey appointed CEO of Countplus (ASX:CUP)

Investment services company CountPlus (ASX:CUP) has appointed Hugh Humphrey as the company's CEO, effective July 1.

" ASX employee tests positive for Covid-19

The ASX says an employee has contracted Covid-19.

" ASIC launches official investigation into ASX market outage

The ASX has confirmed today it is officially under investigation from the Australian Securities and Investments…

" ASX sheds more light on last week’s market tech failure

The Australian Securities Exchange has shed some more light on the nature of last week's market…